Safe and effective use of viral vectors for gene therapeutics requires versatile control over their delivery to target sites in human subjects. We have developed a strategy for the creation of adenoviral vectors that possess conditional infectivity. The adenoviral vectors used were inactivated chemically such that they had little or no ability to infect cells. However, when such chemically inactivated adenoviral vectors were conjugated to the surfaces of appropriate microbeads and the resulting adenovirus-microbead conjugates were provided with the ability to associate stably with cells, the infectivity of these adenoviral vectors was restored. For certain target cell lines, the infectivity of such adenovirusmicrobead conjugates became even higher than that of free, unmodified adenoviral vectors. As a result of the chemical inactivation of viral infectivity, any adenoviral particles that become free from the microbeads should be noninfectious. Thus, these adenoviral vectors have an infectivity that is conditional: They can only infect cells, to which their microbead conjugates come into stable contact. These results lay the groundwork for the creation of targetable adenovirus-microbead conjugates with greater efficacy and safety as delivery agents for gene therapeutics. Gene Therapy (2005) 12, 521-533.
Introduction
Gene therapy using viral vectors as gene transfer agents holds great potential within the future of biomedicine. However, certain obstacles need to be overcome before this potential can be fully realized. Foremost among these obstacles is the issue of the safety of the use of viral vectors in human subjects. A key source of potential danger in the in vivo use of viral vectors stems from the fact that there is little control over the location of transduction sites by viral vectors once they are within the body. In the majority of in vivo gene therapy protocols, viral vectors are administered into the body, often at the target tissue or organ, in the form of free viral particles. Under such conditions, the administered viral particles can travel, without control, beyond the site of administration. This can lead to uncontrolled transduction of nontarget tissues and organs, particularly because viral vectors that are commonly used for gene therapy are highly infectious and have broad tropism. These problems, that is, uncontrolled migration of viral vectors beyond the desired target sites and subsequent transduction of nontarget tissues and organs, have generated genuine safety concerns for gene therapy.
To actualize the comprehensive use of viral vectors for in vivo gene therapy applications, creative solutions to these safety concerns must be found. For certain gene therapy protocols, such as for cancer therapy, strategies are being developed that provide viral vectors with the ability to infect certain cell types specifically. Attempts have been made to genetically engineer viral envelope proteins and capsid-surface proteins to contain binding reagents for cell-surface molecules present on the cell types of interest. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] While a wide variety of strategies have been attempted, success of this approach has been seen in a limited number of cases. When the desired sites of genetic transduction are known, focused administration of viral vectors to the target sites can be used. However, even with such focused administration, free viral particles often migrate away from the target site, resulting in the uncontrolled transduction of nontarget tissues and organs that are distant from the administration site. 5, [16] [17] [18] [19] [20] [21] [22] This problem may become more serious when target cell types are poorly permissive to infection by the viral vector species used. One strategy to reduce the migration of viral vectors from the target site involves the use of viral particles that are attached stably to the surfaces of microbeads (or other solid supports). [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] We and others recently demonstrated that such virusmicrobead conjugates bearing adenoviral and adenoassociated viral vectors have infectivities that are equivalent to or greater than those of free viral vectors in solution. Virus-microbead conjugates can be administered in a manner similar to free viral particles. However, because of the large dimensions and masses of such conjugates, their migration from the administration site is severely limited, allowing the delivery of viral vectors with greater site specificity.
In the present work, we attempted to enhance the efficacy of this strategy for the delivery of adenoviral vectors using virus-microbead conjugates. A particular focus was placed on the enhancement of the safety of the use of adenoviral vectors by minimizing uncontrolled transduction of nontarget tissues and organs. In a newly developed format, the adenoviral vectors used have been inactivated chemically, such that they have little to no infectivity in their free form. However, when such chemically inactivated adenoviral particles are conjugated to the surfaces of appropriate microbeads that can bring the resulting conjugates into stable contact with target cells, their infectivity can be restored to levels comparable to or even greater than that of free, unmodified adenoviral vectors. Thus, the delivered adenoviral vectors have an infectivity that is conditional: They can only infect cells, to which their microbead conjugates come into stable contact. Even if some viral particles become free from the conjugated microbeads, they are noninfectious in their free form, thereby minimizing uncontrolled transduction of nontarget tissues and organs by viral particles that have migrated from the administration site. This should allow the location of the transduction by adenoviral vectors to be controlled in a versatile manner and provide the delivery of adenoviral vectors with considerable safety enhancement.
Results

Chemical inactivation of the infectivity of adenoviral vectors by biotinylation
We previously showed that biotin moieties can be conjugated covalently to the surfaces of adenoviral particles, while retaining their infectivity, by biotinylation using sulfo-NHS-LC-biotin (Pierce Chemical) as the biotinylation reagent. 23, 26 By using the extremely tight interaction between the protein (strept)avidin and its ligand biotin, [27] [28] [29] such biotinylated adenoviral particles can be attached stably onto the surfaces of microbeads, on which streptavidin is immobilized covalently at high densities (streptavidin-coated microbeads). When streptavidin-coated silica microbeads, which have high specific gravity (1.95 g/cm 3 ), were used as virus carriers, the resulting adenovirus-microbead conjugates showed much higher infectivity than free, unmodified adenoviral vectors, when analyzed in vitro using adherent target cells. 23 The most likely mechanism of this infectivity enhancement involves the formation of the stable contact of adenovirus-microbead conjugates to the cell surface due to the gravitational force, derived from the high specific gravity of the conjugated microbeads. This notion was supported by efficient, focused transduction of target cells by biotinylated adenoviral vectors, when they were attached to streptavidin-coated paramagnetic microparticles and the resulting conjugates were allowed to contact with cells by magnetic force. 23 These results suggest that adenovirus-microbead conjugates can efficiently transduce target cells when they are made capable of associating stably with cells. These results also raise the question whether the maintenance of the infectivity of the conjugated adenoviral particles is required for the infection of cells by adenovirus-microbead conjugates. Such conjugates showed even higher infectivities on certain cell lines than free adenoviral vectors. 23 Thus, even if their natural infectivity has been severely reduced or completely ablated in their free form due to the inability of viral particles to associate stably with cells, the delivery of such adenoviral vectors in the form of adenovirus-microbead conjugates to target cells might allow conjugated adenoviral particles to infect cells, as long as other functionalities of the viral vectors are maintained.
To address whether the maintenance of the infectivity of conjugated adenoviral vectors is required for infection by adenovirus-microbead conjugates, the infectivity of adenoviral vectors was inactivated chemically. We used an adenoviral vector (Ad5.CMV-LacZ; Qbiogene), which carries the transducable lacZ (b-galactosidase) gene under the control of the human cytomegalovirus (CMV) immediate-early promoter. Our previous study showed that the infectivity of adenoviral vectors can be inactivated by biotinylation using relatively high concentrations of a water-soluble version of the photocleavable biotinylation reagent NHS-PC-LC-biotin (see Pandori et al 30 for the structures of these biotinylation reagents). The disruption of the ability of adenoviral particles to bind to target cells was found to be the primary cause of the inhibition of the viral infectivity. This suggests that treatment with sulfo-NHS-LC-biotin at relatively high concentrations could also make adenoviral vectors noninfectious, while maintaining their intrinsic ability to infect cells by specifically disrupting the ability of adenoviral particles to bind to target cells.
Ad5.CMV-LacZ was treated with sulfo-NHS-LC-biotin at 5 mg/ml, at which concentration a water-soluble version of NHS-PC-LC-biotin effectively ablated the infectivity of adenoviral vectors. 30 After nonvirionassociated biotinylation reagent was removed by repeated ultrafiltration, the infectivity of the resulting biotinylated adenoviral vectors was analyzed by using the following four cell lines as targets: C6 (rat glioma), Neuro-2a (mouse neuroblastoma), HeLa (human cervical epithelial adenocarcinoma), and D-17 (canine osteosarcoma). For all of these cell lines, Ad5.CMV-LacZ became nearly or completely noninfectious when treated with sulfo-NHS-LC-biotin at a concentration of 5 mg/ml ( Figure 1 ). This demonstrates that adenoviral vectors can be effectively inactivated chemically by treatment with 5 mg/ml sulfo-NHS-LC-biotin (termed overbiotinylation).
Chemically inactivated Ad5.CMV-LacZ, prepared by overbiotinylation as above, was analyzed by Western blotting analysis following SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) to identify biotinylated viral components. Purified, overbiotinylated Ad5.CMV-LacZ was disrupted and denatured by heating in boiling water for 5 min in the presence of 1% SDS. Then, denatured viral proteins were separated by SDS-PAGE using a 4-20% polyacrylamide gradient gel (Pierce Chemical) and then transferred from the gel onto PVDF (polyvinylidene fluoride) membrane (Millipore). The resulting blot was incubated with a streptavidinperoxidase conjugate (Pierce Chemical), which should bind specifically to biotinylated viral proteins on the blot. Bound streptavidin-peroxidase conjugates on the blot were detected by a peroxidase-mediated Adenoviral vectors with conditional infectivity MW Pandori and T Sano chemiluminescence reaction using an ECL Plus Western Blotting Detection Kit (Amersham Biosciences) ( Figure 2 ). A control sample was prepared by disrupting and denaturing unmodified Ad5.CMV-LacZ by heating in boiling water for 3 min in the presence of 1% SDS, followed by overbiotinylation of denatured viral proteins with 5 mg/ml sulfo-NHS-LC-biotin. Since viral proteins had been fully denatured prior to the reaction, the degree of biotinylation of each viral protein species should be almost purely dependent on the number of primary amino groups, derived from the N-terminus and lysine residues. The control sample was analyzed in the same manner as overbiotinylated Ad5.CMV-LacZ. The control sample, which was prepared by overbiotinylation of denatured adenoviral proteins, shows three major bands of biotinylated proteins on the blot, migrating at approximately 4180, 119, and 67 kDa (left lane, Figure 2 ). The known molecular masses of adenoviral proteins and their relative abundance in the virion 31, 32 were used to estimate these biotinylated protein species. A biotinylated protein band with a high molecular mass of greater than 180 kDa may consist of aggregates of viral proteins or contaminants of the Ad5.CMV-LacZ preparation used, since no individual polypeptides of adenoviral proteins have such high molecular masses. A similar protein band, consisting of contaminant proteins, was previously seen in SDS-PAGE analysis of purified adenoviral vector preparations. 32 The 119-kDa and 67-kDa bands of biotinylated proteins should correspond to pII (hexon protein, 967 residues), and a mixture of pIII (penton base protein, 571 residues) and pIV (fiber protein, 582 residues), respectively. In addition to these major bands of biotinylated proteins, a few minor bands of biotinylated proteins are seen on the Figure 2 Western blotting analysis of overbiotinylated adenoviral vectors. Purified, overbiotinylated Ad5.CMV-LacZ, prepared as in Figure 1 , was disrupted and denatured by heating in boiling water for 5 min in the presence of 1% SDS. Denatured viral proteins were separated by SDS-PAGE using a 4-20% polyacrylamide gradient gel (Pierce Chemical), and then proteins were transferred from the gel onto PVDF membrane (Millipore). The resulting blot was incubated with a SuperBlock Blocking Buffer (Pierce Chemical), followed by the incubation at room temperature for 1 h with a streptavidin-peroxidase conjugate (Pierce Chemical) (1/40 000 dilution in PBS containing 50% SuperBlock Blocking Buffer). After unbound conjugates were removed, bound streptavidin-peroxidase conjugates on the blot were detected by a peroxidase-mediated chemiluminescence reaction using an ECL Plus Western Blotting Detection Kit Figure 1 Infectivity analysis of overbiotinylated adenoviral vectors and their conjugates with avidin-coated silica microbeads. Ad5.CMV-LacZ was treated with 5 mg/ml sulfo-NHS-LC-biotin (overbiotinylation), followed by the removal of nonvirion-associated biotinylation reagent by repeated ultrafiltration. The resulting overbiotinylated Ad5.CMV-LacZ was attached to avidin-coated silica microbeads (diameter, 0.50 mm; specific gravity, 1.95 g/cm 3 ) at 3.06 viral particles per microbead. The infectivities of free, overbiotinylated Ad5.CMV-LacZ (B) and its conjugates with avidin-coated silica microbeads (C) were analyzed on the following cell lines: C6 (rat glioma), Neuro-2a (mouse neuroblastoma), HeLa (human cervical epithelial adenocarcinoma), and D-17 (canine osteosarcoma). Cells were cultured in wells (15.5 mm in diameter; 5 Â 10 4 cells/well) at 371C for 24 h. Overbiotinylated Ad5.CMV-LacZ or its conjugates with avidincoated silica microbeads (a total volume of 1 ml containing 1.2 Â 10 7 viral particles or 5 ml containing 6 Â 10 7 viral particles) was added to each well, and cells were cultured at 371C for 48 h. Cells were fixed with 0.5% glutaraldehyde and stained for b-galactosidase activity by using X-gal as the substrate. The numbers of infected, lacZ-expressing cells for five randomly chosen microscopic field (2.27 mm 2 ) in each well were counted under a light microscope. Free, unmodified Ad5.CMV-LacZ was analyzed in the same manner as a control (A). Each datum shown is the average number of infected cells per microscopic field (2.27 mm 2 ) that has been normalized at 1.2 Â 10 7 viral particles/well. Standard deviations of the means (n ¼ 5) are shown with vertical lines. Two data for each of overbiotinylated Ad5.CMV-LacZ (B) and its microbead conjugates (C) are derived from two independently prepared samples to assess the reproducibility of data.
Adenoviral vectors with conditional infectivity MW Pandori and T Sano blot in a molecular mass range between 20 and 34 kDa. These bands of biotinylated proteins are likely to consist primarily of pVI (a hexon-associated protein, 217 residues) and pVII (the major component of the viral core, 174 residues).
In contrast to the control sample, overbiotinylated Ad5.CMV-lacZ shows an almost exclusive band of biotinylated proteins at approximately 119 kDa (right lane, Figure 2) . From its molecular mass and the corresponding band in the control sample (left lane), the 119-kDa protein band is very likely to correspond to pII (hexon protein). The preferential biotinylation of pII is explainable by the facts that pII is the most abundant viral protein, and that pII is exposed at the viral surface, providing greater accessibility by the hydrophilic biotinylation reagent used (sulfo-NHS-LC-biotin). No apparent biotinylation of pIII (penton base protein) and pIV (fiber protein), both of which are located near the viral surface, was seen on the blot. This result does not exclude the possibility that pIII and pIV are modified by overbiotinylation of adenoviral vectors. Since these viral proteins exist in much smaller amounts in the virion than pII, their biotinylation may be difficult to detect by the analytical method used unless they are biotinylated at much greater efficiencies than pII.
Infectivity of chemically inactivated adenoviral vectors when delivered as microbead conjugates
The infectivity of adenoviral vectors, which had been inactivated chemically by overbiotinylation (ie, treatment with 5 mg/ml sulfo-NHS-LC-biotin), was investigated when they were delivered to target cells in the form of microbead conjugates. Avidin-coated silica microbeads, which have high specific gravity (specific gravity, 1.95 g/cm 3 ; diameter, 0.50 mm; Gerlinde Kisker GbR), were used as virus carriers. Purified, overbiotinylated Ad5.CMV-LacZ was mixed with avidin-coated microbeads at a ratio of approximately three viral particles per microbead, followed by centrifugation to separate adenovirus-microbead conjugates. The efficiency of immobilization of overbiotinylated Ad5.CMV-LacZ on avidin-coated microbeads was estimated by the analysis of the supernatant fractions for the presence of adenoviral particles using the polymerase chain reaction (PCR). A set of primers was used in PCR to amplify a segment of the adenoviral genome, followed by agarose gel electrophoretic analysis of PCR products. When free Ad5.CMV-LacZ was subjected to PCR, a specific PCR product was detected, as expected (data not shown). As few as 6 Â 10 3 adenoviral particles were detectable by this PCR assay. In contrast, when the supernatant fraction (which should contain unconjugated adenoviral particles) of a mixture of avidin-coated microbeads with overbiotinylated Ad5.CMV-LacZ (3.6 Â 10 6 adenoviral particles) was analyzed in the same manner, no PCR products were detected (data not shown). This result reveals that all of the overbiotinylated adenoviral particles added had been attached to the surfaces of avidin-coated microbeads. This result is in agreement with our previous study, where all of the adenoviral vectors, which were biotinylated at a lower concentration (15 mg/ml) of sulfo-NHS-LC-biotin, were bound to the surfaces of streptavidin-coated microbeads. 23 The infectivity of adenovirus-microbead conjugates, prepared by using overbiotinylated Ad5.CMV-LacZ and avidin-coated silica microbeads as above, was investigated ( Figure 1 ). When C6 cells, which are poorly permissive to adenoviral infection, were used as target cells, free, unmodified Ad5.CMV-LacZ showed relatively low infectivity. Overbiotinylation of Ad5.CMVLacZ ablated the viral infectivity completely. However, when these overbiotinylated adenoviral vectors were delivered to target cells in the form of conjugates with avidin-coated microbeads, they had an infectivity approximately 45-fold higher than free, unmodified adenoviral vectors. When Neuro-2a cells, which are slightly more permissive to adenoviral infection than C6, were used as targets, overbiotinylated Ad5.CMV-LacZ showed very limited infectivity. However, when delivered to target cells as conjugates with avidin-coated microbeads, overbiotinylated Ad5.CMV-LacZ showed an infectivity that is several times higher than free, unmodified adenoviral vectors. Similarly, when HeLa cells, the permissivity of which to adenoviral infection is similar to that of Neuro-2a cells, were used, free, overbiotinylated Ad5.CMV-LacZ showed very limited infectivity but had an infectivity equivalent to free, unmodified adenoviral vectors when delivered in the form of conjugates with avidin-coated microbeads. For D-17 cells that are highly permissive to adenoviral infection, overbiotinylation made Ad5.CMV-LacZ almost completely noninfectious. The delivery of these overbiotinylated adenoviral vectors to target cells as conjugates with avidin-coated microbeads resulted in substantial restoration of infectivity, as seen with the other three cell lines described above. However, the restored infectivity was approximately 15-25% of the infectivity of free, unmodified Ad5.CMVLacZ, unlike with the other three cell lines, for which the infectivity of overbiotinylated Ad5.CMV-LacZ was restored to levels that were equivalent to or greater than that of free, unmodified adenoviral vectors when they were delivered to target cells in the form of conjugates with avidin-coated microbeads.
These results demonstrate that overbiotinylation using sulfo-NHS-LC-biotin can effectively ablate the infectivity of adenoviral vectors in their free form, and that such chemically inactivated adenoviral vectors can infect target cells efficiently when they are delivered to target cells in the form of conjugates with avidincoated microbeads that have high specific gravity. In the infection of cells by chemically inactivated adenoviral vectors that are conjugated to avidin-coated microbeads, it is likely that gravitational force, derived from the high specific gravity of the conjugated microbeads, brings the conjugated adenoviral particles into stable contact with target cells. This may restore the infectivity of otherwise noninfectious viral particles in their free form. A comparison of the infectivity on the four different cell lines suggests that the permissivity of target cells to infection by free adenoviral vectors serves as a determinant for the level of infectivity restoration of overbiotinylated adenoviral vectors by their delivery in the form of conjugates with avidin-coated microbeads. It appears that the level of infectivity restoration becomes profound for cell lines that are poorly permissive to infection by free adenoviral vectors.
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Role of the coxsackie-adenovirus receptor (CAR) in the infection by adenovirus-microbead conjugates
The primary cell-surface receptor for adenovirus, the CAR, [33] [34] [35] plays a key role in the infection of cells by adenoviral vectors. The infection process is initiated by the binding of the viral fiber protein to CAR. Thus, the amount of CAR on the cell surface serves as the primary determinant for the permissivity of cells to adenoviral infection. As described above, the infectivity restoration of chemically inactivated adenoviral vectors by their delivery in the form of conjugates with avidin-coated microbeads may involve the formation of direct, stable contact of conjugated adenoviral particles with the cell surface by gravitational force, derived from the high specific gravity of conjugated microbeads. Under such conditions, the role of CAR in infection might be altered, as compared to that for free, unmodified adenoviral vectors. To test this, the infectivity of chemically inactivated adenoviral vectors, attached to avidin-coated silica microbeads, was analyzed in the presence and absence of antibodies against CAR. A mouse monoclonal antibody against human CAR (clone E1-1; Abcam, Ltd), was used, which has been shown to block the binding of adenoviral particles to cell-surface CAR. 36 HeLa cells were used as targets because of the specificity of this monoclonal antibody for human CAR.
The ability of the anti-CAR monoclonal antibody E1-1 to inhibit the infection of HeLa cells by free adenoviral vectors was initially tested. This anti-CAR monoclonal antibody reduced the infectivity of free, unmodified Ad5.CMV-LacZ only by 50% (data not shown) under the conditions used for the infectivity analysis shown in Figure 1 . Although the presence of the anti-CAR antibody had little effect on the infectivity of adenovirus-microbead conjugates, prepared by using overbiotinylated Ad5.CMV-LacZ and avidin-coated silica microbeads (data not shown), the role of CAR in their infection was difficult to determine under the conditions where the effect of the anti-CAR antibody on the infectivity of free adenoviral vectors was only modest. To facilitate the assessment of the role of CAR in infection by adenovirus-microbead conjugates, experimental conditions were modified. In particular, a higher virus-tocell ratio (approximately 2400) and a greater amount of the anti-CAR monoclonal antibody were used where the effect of the anti-CAR antibody on the infection by free adenoviral vectors was greater.
The infectivity of free, unmodified Ad5.CMV-LacZ for HeLa cells was reduced by approximately four-fold in the presence of excess amounts of the anti-CAR monoclonal antibody (Figure 3 ). This result confirms the ability of this anti-CAR monoclonal antibody to inhibit the infection by free adenoviral vectors, shown in a previous study. 36 The same analysis was performed with Ad5.CMV-LacZ, which had been inactivated by overbiotinylation and subsequently attached to the surfaces of avidin-coated silica microbeads at approximately three viral particles per microbead. In the absence of the anti-CAR antibody, the infectivity of adenovirusmicrobead conjugates became greater than that of free, unmodified Ad5.CMV-LacZ, unlike the results shown in Figure 1 , where their infectivity for HeLa cells was equivalent to that of free Ad5.CMV-LacZ. This is likely derived from the differences in experimental conditions, particularly the use of a higher virus-to-cell ratio in this experiment. The infectivity of adenovirus-microbead conjugates was hardly affected by the presence of excess amounts of the anti-CAR monoclonal antibody under the conditions where that of free Ad5.CMV-LacZ was reduced by approximately four-fold. This result implies that, when delivered to target cells in the form of adenovirus-microbead conjugates, chemically inactivated adenoviral vectors may infect cells in a manner that is less dependent on the binding to cell-surface CAR than free, unmodified adenoviral vectors.
Role of integrins in the infection by adenovirusmicrobead conjugates
In the infection of cells by adenovirus, the binding of viral-surface fiber proteins to cell-surface CAR is Abcam, Ltd) was added to wells (80 ml/well) and incubated at 41C for 2 h. To control wells, PBS (80 ml/well) was added and incubated in the same manner. Then, adenovirus-microbead conjugates, prepared by using overbiotinylated Ad5.CMV-LacZ and avidin-coated silica microbeads (3.06 viral particles per microbead), were added to each well that had been incubated with anti-CAR antibodies or PBS. Cells were incubated at 371C for 2.5 h and then washed twice with DMEM containing 10% FBS. Then, cells were cultured with fresh medium at 371C for 48 h, followed by the analysis of lacZ expression using X-gal as the substrate (B), as in Figure 1 . Free, unmodified Ad5.CMV-LacZ was analyzed in the same manner as a control (A). Each datum shown is the average number of infected cells per microscopic field (2.27 mm 2 ). Standard deviations of the means (n ¼ 4) are shown with vertical lines.
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followed by the interaction of the viral penton base with cell-surface a v b 3 and a v b 5 integrins. This interaction is essential for the internalization of bound viral particles into cells. When chemically inactivated adenoviral vectors are delivered to target cells in the form of conjugates with avidin-coated microbeads that have high specific gravity, the formation of direct, stable contact of conjugated adenoviral particles with the cell surface may be driven by gravitational force, derived from the high specific gravity of conjugated microbeads. Under such conditions, the role of the interaction of the viral penton base with cell-surface integrins might be altered, similar to the binding of the viral fiber protein to cell-surface CAR (Figure 3 37 HeLa cells were used as targets because of the specificity of this monoclonal antibody for human integrin a v .
In the presence of excess amounts of the anti-integrin a v antibody, the infectivity of free, unmodified Ad5.CMV-LacZ for HeLa cells was reduced by approximately 4.5-fold (Figure 4 ). This result is in agreement with a previous study 37 and confirms the ability of this monoclonal antibody to inhibit the infection of human cells by free, unmodified adenoviral vectors. The infectivity of chemically inactivated Ad5.CMV-LacZ, attached to the surfaces of avidin-coated silica microbeads at approximately three viral particles per microbead, was also analyzed in the presence of excess amounts of the anti-integrin a v antibody. Similar to free, unmodified Ad5.CMV-LacZ, the infectivity of chemically inactivated Ad5.CMV-LacZ, attached to the surfaces of avidin-coated silica microbeads, was reduced by approximately fourfold by the presence of the anti-integrin a v antibody. This result suggests that infection of cells by chemically inactivated adenoviral vectors, when delivered in the form of adenovirus-microbead conjugates, may involve an interaction with cell-surface integrins using the viral penton base in a manner that is the same as or similar to that of free, unmodified adenoviral vectors.
Modulation of the infectivity of chemically inactivated adenoviral vectors
As stated above, the infectivity restoration of chemically inactivated adenoviral vectors by their delivery to target cells in the form of conjugates with avidin-coated microbeads is likely to involve the formation of direct, stable contact of conjugated adenoviral particles to the cell surface by gravitational force, derived from the high specific gravity of the conjugated microbeads. This suggests that, by varying the specific gravity of microbeads that are used as virus carriers, the infectivity of chemically inactivated adenoviral vectors could be modulated. In particular, when microbeads with physiological specific gravity are used as virus carriers, the resulting adenovirus-microbead conjugates should be able to migrate freely in physiological solution, similar to free, unmodified viral particles. Thus, unlike the case where microbeads with high specific gravity are used as virus carriers, conjugated viral particles may be unable to make stable contact with target cells, because of the absence of a force that promotes their contact to cells, such as gravitational force. The addition of the large mass of each microbead should also reduce the ability of the conjugated viral particles to make stable contact with target cells when the specific gravity of the conjugates is in the physiological range. To test this hypothesis, streptavidin-coated polystyrene microbeads, the specific gravity of which is in the physiological range (1.06 g/cm 3 ; diameter, 0.53 mm; Bangs Laboratories), were used as virus carriers. A fluorophore (termed Dragon Green; l ex , 480 nm; l em , 520 nm) is entrapped within these microbeads, allowing their easy detection and localization. A monoclonal antibody against human integrin a V (clone AV1, mouse IgG 1 , hybridoma supernatant; Chemicon) (150 ml of a 1/2 dilution per well) was added to wells (150 ml of a 1/2 dilution per well) and incubated at 41C for 1 h. To control wells, PBS (150 ml/well) was added and incubated in the same manner. Then, adenovirus-microbead conjugates, prepared by using overbiotinylated Ad5.CMV-LacZ and avidin-coated silica microbeads (3.17 viral particles per microbead), were added to each well that had been incubated with anti-integrin a V antibodies or PBS. Cells were incubated at 371C for 48 h, followed by the analysis of lacZ expression using X-gal as the substrate (B), as in Figure 1 . Free, unmodified Ad5.CMV-LacZ was analyzed in the same manner as a control (A). Each datum shown is the average number of infected cells per microscopic field (2.27 mm 2 ). Standard deviations of the means (n ¼ 5) are shown with vertical lines.
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Ad5.CMV-LacZ was chemically inactivated by overbiotinylation (treatment with 5 mg/ml sulfo-NHS-LCbiotin) and purified, as described above. These chemically inactivated adenoviral vectors showed little to no infectivity on the three cell lines tested (Neuro-2a, HeLa, and D-17) (Figure 5 ), in agreement with the results shown in Figure 1 . The chemically inactivated Ad5.CMV-LacZ was attached to the surface of streptavidin-coated polystyrene microbeads at a ratio of 2.5 viral particles per microbead. The resulting adenovirusmicrobead conjugates remained almost noninfectious for the three cell lines tested ( Figure 5 ), in contrast to their delivery in the form of conjugates with avidincoated microbeads with high specific gravity where considerable restoration of the infectivity was seen (Figure 1 ). This result supports the hypothesis, described Figure 5 Infectivity analysis of adenovirus-microbead conjugates, prepared by using overbiotinylated adenoviral vectors and streptavidin-coated polystyrene microbeads, and those with the coattachment of biotinylated Con A. Ad5.CMV-LacZ was overbiotinylated by treatment with 5 mg/ml sulfo-NHS-LC-biotin, followed by the removal of nonvirion-associated biotinylation reagent by repeated ultrafiltration. The resulting overbiotinylated Ad5.CMV-LacZ was attached to streptavidin-coated polystyrene microbeads (diameter, 0.53 mm; specific gravity, 1.06 g/cm 3 ) at 2.5 viral particles per microbead. The infectivities of free, overbiotinylated Ad5.CMV-LacZ (B) and its conjugates with streptavidin-coated polystyrene microbeads (C) were analyzed on the cell lines Neuro-2a, HeLa, and D-17. Cells were cultured in wells (15.5 mm in diameter; 5 Â 10 4 cells/well) at 371C for 24 h. Overbiotinylated Ad5.CMV-LacZ or its conjugates with streptavidin-coated polystyrene microbeads (a total volume of 1 ml containing 1.2 Â 10 7 viral particles or 5 ml containing 6 Â 10 7 viral particles) was added to each well, and cells were cultured at 371C for 48 h. Cells were fixed with 0.5% glutaraldehyde and stained for b-galactosidase activity by using X-gal as the substrate. The numbers of infected, lacZ-expressing cells for five randomly chosen microscopic field (2.27 mm 2 ) in each well were counted under a light microscope. Free, unmodified Ad5.CMV-LacZ was analyzed in the same manner as a control (A). The coattachment of biotinylated Con A to the microbead surface was carried out by the addition of 2 mg biotinylated Con A (Vector Laboratories) to adenovirus-microbead conjugates (4.6 Â 10 7 viral particles/1.84 Â 10 7 microbeads) prepared as above, followed by the removal of unbound biotinylated Con A. Similar conjugates were also prepared by the same method using biotinylated alkaline phosphatase (Pierce Chemical) (2 mg/ 4.6 Â 10 7 viral particles/1.84 Â 10 7 microbeads), in place of biotinylated Con A, and used as controls. The infectivities of these conjugates were analyzed in the same manner as above (D and E). Each datum shown is the average number of infected cells per microscopic field (2.27 mm 2 ) that has been normalized at 1.2 Â 10 7 viral particles/well. Standard deviations of the means (n ¼ 5) are shown with vertical lines. Two data for each of B-E are derived from two independently prepared samples to assess the reproducibility of data.
above, that chemically inactivated adenoviral vectors remain noninfectious when they are delivered to target cells in the form of microbead conjugates with physiological specific gravity. This result also supports the notion that the infectivity restoration of chemically inactivated adenoviral vectors, when delivered to target cells in the form of microbead conjugates with high specific gravity, involves the formation of direct, stable contact of conjugated adenoviral particles to the cell surface by gravitational force.
The result that chemically inactivated adenoviral vectors remain noninfectious when attached to microbeads with physiological specific gravity suggests the possibility that such adenovirus-microbead conjugates could become infectious if they could be made capable of associating stably with the cell surface, as seen with the conjugates with microbeads with high specific gravity. To test this, a binding reagent for cell-surface molecules was attached to the surfaces of microbeads with physiological specific gravity, onto which chemically inactivated adenoviral vectors had been conjugated. We chose concanavalin A (Con A), one of the most well-studied lectins, as the binding reagent for cell-surface molecules. Con A binds to a-D-glucopyranosyl and a-D-mannopyronosyl moieties, which exist abundantly in carbohydrate chains on mammalian cells (for reviews, see Lis and Sharon 38, 41 , Sharon and Lis. 39, 40 ) An excess amount of a biotinylated form of Con A (Vector Laboratories) was added to streptavidin-coated polystyrene microbeads with physiological specific gravity, to which overbiotinylated Ad5.CMV-LacZ had been attached at 2.5 viral particles per microbead. Unbound biotinylated Con A was removed, and the resulting conjugates were analyzed for their infectivity on Neuro-2a, HeLa, and D-17 cells ( Figure 5 ). As controls, similar conjugates were prepared by using a biotinylated alkaline phosphatase (Pierce Chemical), which has no known ability to associate with the cell surface, in place of biotinylated Con A, and analyzed in the same manner.
For all of the three cell lines tested, chemically inactivated Ad5.CMV-LacZ, attached to streptavidincoated microbeads with physiological specific gravity, remained noninfectious when biotinylated alkaline phosphatase was coattached to the microbeads ( Figure  5 ). In contrast, the coattachment of biotinylated Con A to the microbead surface resulted in considerable restoration of the infectivity of the conjugated adenoviral vectors. For Neuro-2a and HeLa cells, which have relatively poor permissivity to adenoviral infection, the infectivity of chemically inactivated Ad5.CMV-LacZ was restored to levels that exceeded the infectivity of free, unmodified Ad5.CMV-LacZ. Similarly, for D-17 cells that are highly permissive to adenoviral infection, the infectivity of chemically inactivated Ad5.CMV-LacZ was restored but to the level that is approximately 10% of the infectivity of free, unmodified adenoviral vectors. These results support the hypothesis, described above, that the infectivity of chemically inactivated adenoviral vectors, which are attached to microbeads with physiological specific gravity, can be restored if they are made capable of associating stably with target cells by the coattachment of a binding reagent for the cell surface, such as Con A, on the microbead surface. These results also showed that the infectivity restoration of chemically inactivated adenoviral vectors, when delivered in the form of microbead conjugates bearing Con A, became greater for cell lines that are poorly permissive to infection by free adenoviral vectors. This is similar to the restoration of their infectivity when delivered to cells in the form of microbead conjugates with high specific gravity (Figure 1) .
We also investigated the ability of adenovirusmicrobead conjugates to associate with target cells. Adenovirus-microbead conjugates were prepared by using chemically inactivated Ad5.CMV-LacZ and streptavidin-coated polystyrene microbeads with physiological specific gravity, with and without the coattachment of biotinylated Con A, as above. These conjugates were incubated with Neuro-2a cells, and their association with target cells was determined from cell-associated fluorescence, derived from the conjugated microbeads, under a fluorescence microscope (Figure 6 ).
When adenovirus-microbead conjugates without biotinylated Con A were used, very low cell-associated fluorescence was seen, indicating that these conjugates were incapable of associating stably with cells. This result supports the hypothesis, described above, that the severely reduced infectivity of these conjugates is derived from their inability to associate with target cells. In contrast, intense cell-associated fluorescence was Figure 6 Microscopic analysis of cell association of adenovirus-microbead conjugates, prepared by using overbiotinylated adenoviral vectors and streptavidin-coated polystyrene microbeads. Adenovirus-microbead conjugates, with and without the coattachment of biotinylated Con A, were prepared as described in the legend to 
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The mixtures were incubated at 41C for 4 h with gentle rocking, followed by the washing of cells with PBS to remove unbound conjugates. The resulting samples were subjected to the quantitation of cell-associated adenoviral particles by quantitative PCR using primers and a probe that are specific to a segment of the Ad5.CMV-LacZ genome ( Figure 7) . As a control, adenovirus-microbead conjugates without the coattachment of biotinylated Con A were analyzed in the same manner.
When adenovirus-microbead conjugates without biotinylated Con A were used, a very small amount of cellassociated adenoviral vectors was detected by quantitative PCR. The coattachment of biotinylated Con A to adenovirus-microbead conjugates resulted in a considerable increase of the amount of cell-associated adenoviral vectors. These results are in agreement with those in Figure 6 . When methyl-a-D-glucopyranoside and methyl-a-D-mannopyranoside were present in the mixture of target cells with adenovirus-microbead conjugates with the coattachment of biotinylated Con A, the amount of cell-associated adenoviral vectors was greatly reduced to a level similar to that of the same conjugates without biotinylated Con A. These results demonstrate that enhanced cell association of adenovirus-microbead conjugates upon coattachment of biotinylated Con A was indeed derived from the ability of the attached Con A to bind to carbohydrate moieties on the cell surface.
Discussion
We have developed a strategy for the creation of adenoviral vectors that possess a conditional infectivity. Treatment with relatively high concentrations of a biotinylation reagent, sulfo-NHS-LC-biotin, effectively ablated the infectivity of adenoviral vectors. Such chemically inactivated adenoviral vectors had little to no infectivity in their free form. However, when such chemically inactivated adenoviral vectors were conjugated to the surfaces of microbeads and the resulting conjugates were provided with the ability to associate stably with cells, the infectivity of these adenoviral vectors was restored. Thus, the only cells that can be transduced by chemically inactivated adenoviral vectors are those that come into direct, stable contact with adenovirus-microbead conjugates. Two different systems were used to provide these adenovirus-microbead conjugates with the ability to associate stably with target cells. One system involves the use of microbeads with high specific gravity as virus carriers, which drive stable association of adenovirus-microbead conjugates with target cells by gravitational force (Figure 1) . The other system involves the use of microbeads with Quantitative PCR analysis of cell association of adenovirusmicrobead conjugates, prepared by using overbiotinylated adenoviral vectors and streptavidin-coated polystyrene microbeads. Adenovirusmicrobead conjugates (three viral particles per microbead) with the coattachment of biotinylated Con A (in 15 ml PBS containing 7.2 Â 10 7 viral particles/2.4 Â 10 7 microbeads), prepared as in Figure 5 , were mixed with suspensions of HeLa cells (7.5 Â 10 5 cells in 5 ml DMEM containing 10% FBS) in the absence or presence of 200 mM methyl-a-D-glucopyranoside and 200 mM methyl-a-D-mannopyranoside. The mixtures were incubated at 41C for 4 h with gentle rocking, followed by the washing of cells with PBS. The resulting cell samples were stored frozen overnight at À201C and then analyzed in duplicate for the amount of cell-associated Ad5.CMV-LacZ by quantitative PCR using a Prism 7700 Sequence Detection System (Applied Biosystems) with a pair of primers and a probe that are specific to a segment of the genome of Ad5.CMV-LacZ. As a control, adenovirus-microbead conjugates without the coattachment of biotinylated Con A were analyzed in the same manner. Known amounts of free, unmodified Ad5.CMV-LacZ was used as standards for quantitation. Each datum shown is the average of duplicated measurements, the variation of which is shown with a vertical line.
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physiological specific gravity as virus carriers. Conjugation of chemically inactivated adenoviral vectors to such microbeads maintained their inability to infect cells ( Figure 5) . However, the coattachment of Con A, a lectin used as a binding reagent for cell-surface molecules, to the microbead surfaces allowed the resulting adenovirus-microbead conjugates to associate stably with target cells, resulting in efficient infection of target cells (Figures 5-7) . These results suggest the possibility that adenovirus-microbead conjugates, prepared by using chemically inactivated adenoviral vectors and microbeads with physiological specific gravity, could be made targetable to cells in a cell-type-specific manner by the coattachment of appropriate binding reagents for cellsurface molecules present on the target cells. For example, the coattachment of a monoclonal antibody against a cell-surface molecule could allow the selective targeting of adenovirus-microbead conjugates to cells that express the cell-surface molecule. The fact that such adenovirus-microbead conjugates have little to no infectivity without the coattachment of binding reagents suggests that this strategy could offer great specificity for cell-type-specific transduction of target cells by conjugated adenoviral vectors. The use of microbeads as platforms for both chemically inactivated adenoviral vectors and binding reagents could also provide this strategy with great versatility.
The infectivity of chemically inactivated adenoviral vectors, attached to microbeads with high specific gravity, was hardly affected by the presence of excess amounts of a monoclonal antibody against CAR, which efficiently inhibited the infection of free adenoviral vectors (Figure 3 ). This suggests that the infection of cells by chemically inactivated adenoviral vectors in the form of microbead conjugates is less dependent on the binding of adenoviral particles to cell-surface CAR. In addition, infectivity restoration of chemically inactivated adenoviral vectors by their delivery in the form of microbead conjugates became more profound for cell lines that are poorly permissive to adenoviral infection. These data imply that the amount of CAR on the cell surface may not serve as the primary determinant for permissivity of a given cell line to infection by adenovirus-microbead conjugates, unlike free adenoviral vectors. It might even be possible that adenovirusmicrobead conjugates can infect cells by a mechanism that does not involve their binding to cell-surface CAR.
In contrast to the effect of the anti-CAR antibody, the infectivity of chemically inactivated adenoviral vectors, attached to microbeads with high specific gravity, was affected significantly by the presence of excess amounts of a monoclonal antibody against integrin a V (Figure 4 ). In particular, the effect of this monoclonal antibody on the infectivity of adenovirus-microbead conjugates was similar to that on the infectivity of free adenoviral vectors. This suggests that the infection of target cells by chemically inactivated adenoviral vectors, when delivered to the surface of cells in the form of adenovirusmicrobead conjugates, may still require the interaction of the viral penton base with cell-surface integrins for internalization of viral particles into cells, as seen with free, unmodified adenoviral vectors.
The gene transfer strategy using chemically inactivated adenoviral vectors, developed in this study, could offer significant enhancements in the use of adenoviral vectors for in vivo gene therapy applications. Adenovirus-microbead conjugates can be administered to target sites in a focused manner, similar to free adenoviral vectors. The large dimensions and masses of the conjugated microbeads should severely limit the migration of the conjugates, resulting in a more site-specific transduction of target sites. The coattachment of a binding reagent for commonly found cell-surface molecules should further limit the migration of the conjugates from administration sites. The conjugated adenoviral vectors have been inactivated chemically and have little to no infectivity in free form. Thus, any adenoviral particles that become free from the microbeads should be noninfectious. This should minimize uncontrolled transduction of nontarget tissues and organs, providing the delivery of adenoviral vectors with considerable safety enhancement.
Materials and methods
Adenoviral vectors
The adenoviral vector Ad5.CMV-LacZ (Qbiogene, Montreal, Canada), derived from adenovirus serotype 5, was used in this study. Ad5.CMV-LacZ carries the bacterial lacZ (b-galactosidase) gene under the control of the human CMV immediate-early promoter, with deletions of the viral E1A, E1B, and E3 genes. Ad5.CMV-LacZ was purified and stored as described previously. 23, 26, 30 
Cell lines
The following four cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and used as target cells: C6 (rat glioma), Neuro-2a (mouse neuroblastoma), HeLa (human cervical epithelial adenocarcinoma), and D-17 (canine osteosarcoma). C6 and HeLa cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (BioWhittaker) supplemented with 10% fetal bovine serum (FBS; BioWhittaker). Neuro2a cells were maintained in Eagle's minimum essential medium supplemented with 10% FBS. D-17 cells were maintained in DMEM supplemented with 6% FBS.
Preparation and infectivity analysis of overbiotinylated adenoviral vectors
Overbiotinylation of Ad5.CMV-LacZ. was performed by using sulfo-NHS-LC-biotin (Pierce Chemical) as the biotinylation reagent. Solid sulfo-NHS-LC-biotin was dissolved in 400 ml Dulbecco's PBS (pH 7.2) containing 2.4 Â 10 9 adenoviral particles to a final concentration of 5 mg/ml. The mixtures were placed on ice in the dark for 2 h. Then, the mixtures were subjected to six rounds of ultrafiltration using ZM-500 centrifugal filtration units (molecular mass cutoff, 500 kDa; Millipore) with PBS containing 0.05% Tween 20 (PBST) as a diluent to remove nonvirion-associated biotinylation reagent.
The infectivity of overbiotinylated Ad5.CMV-LacZ was determined by using the cell lines indicated above as targets. Cells were seeded in wells (15.5 mm in diameter; 5 Â 10 4 cells/well) and cultured at 371C for 24 h. A dilution of overbiotinylated Ad5.CMV-LacZ (a total volume of 1 ml containing 1.2 Â 10 7 viral particles or 5 ml containing 6 Â 10 7 viral particles) was added to each well (volume of culture medium, 1.0 ml/well) and incubated at 371C for 48 h. Cells were fixed with 0.5% ) in each well were counted under a light microscope. Free, unmodified Ad5.CMVLacZ was also analyzed as a control in the same manner.
Western blotting analysis of overbiotinylated adenoviral vectors
Purified, overbiotinylated Ad5.CMV-LacZ, prepared as above, was disrupted and denatured by heating in boiling water for 5 min in the presence of 1% SDS. Then, denatured viral proteins were separated by SDS-PAGE using a 4-20% polyacrylamide gradient gel (Pierce Chemical) with a Tris-HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid) buffer system (Pierce Chemical). Proteins were transferred from the gel onto PVDF membrane (Millipore) by using a semidry blotting unit (Hoefer SemiPhor, Pharmacia Biotech). The resulting blot was incubated with a SuperBlock Blocking Buffer (Pierce Chemical), followed by the incubation at room temperature (B221C) for 1 h with a streptavidin-peroxidase conjugate (1/40 000 dilution in PBS containing 50% SuperBlock Blocking Buffer). After unbound conjugates were removed, bound streptavidin-peroxidase conjugates on the blot were detected by a peroxidase-mediated chemiluminescence reaction using an ECL Plus Western Blotting Detection Kit (Amersham Biosciences) with Kodak BioMax Light film. A control sample was prepared by disrupting and denaturing unmodified Ad5.CMV-LacZ by heating in boiling water for 3 min in the presence of 1% SDS, followed by overbiotinylation of denatured viral proteins with 5 mg/ml sulfo-NHS-LC-biotin. This control sample was analyzed in the same manner as above.
Preparation and infectivity analysis of adenovirusmicrobead conjugates with avidin-coated silica microbeads Ad5.CMV-LacZ was biotinylated with 5 mg/ml sulfo-NHS-LC biotin, followed by the removal of nonvirionassociated biotinylation reagent, as described above. The resulting overbiotinylated Ad5.CMV-LacZ (6 Â 10 8 viral particles in 50 ml) was mixed with 1.96 Â 10 8 avidin-coated silica microbeads (diameter, 0.50 mm; specific gravity, 1.95 g/cm 3 ; Gerlinde Kisker GbR, Steinfurt, Germany). This corresponds to a ratio of 3.06 viral particles per microbead. The mixtures were placed on ice for 30 min with occasional mixing by gentle pipetting. The resulting adenovirus-microbead conjugates were washed with PBST by three rounds of centrifugation at 3200 g for 1.5 min at 41C, with each spin followed by resuspension of the conjugates in 1 ml of fresh PBST. Finally, adenovirusmicrobead conjugates were resuspended in PBS without Tween 20 at a final concentration of 3.92 Â 10 9 microbeads/ml. During these manipulations, no apparent loss of microbeads was seen by visual inspection.
The infectivity of these adenovirus-microbead conjugates was determined by the method described above for overbiotinylated Ad5.CMV-LacZ, except that adenovirus-microbead conjugates were fully dispersed prior to application to target cells. Free, unmodified Ad5.CMVLacZ and free, overbiotinylated Ad5.CMV-LacZ were also analyzed as controls in the same manner.
Infectivity analysis in the presence of monoclonal anti-CAR antibody
HeLa cells were seeded in wells (35 mm in diameter; 1 Â 10 5 cells/well) and cultured at 371C for 24 h. A monoclonal antibody against human CAR (clone E1-1, mouse IgG 1 , hybridoma supernatant; Abcam, Ltd, Cambridge, UK) (80 ml/well) was added to wells (volume of culture medium, 1.0 ml/well) and incubated at 41C for 2 h with gentle mixing. The same volume of PBS was added to control wells and incubated in the same manner. Adenovirus-microbead conjugates were prepared by using overbiotinylated Ad5.CMV-LacZ and avidin-coated silica microbeads (3.06 viral particles per microbead), as described above. These adenovirusmicrobead conjugates were fully dispersed and added to wells containing HeLa cells that had been incubated with anti-CAR antibodies (2.4 Â 10 8 viral particles/ 7.8 Â 10 7 microbeads in 20 ml PBS/well). The same amount of the adenovirus-microbead conjugates was also applied to each control well, to which no anti-CAR antibodies had been added. These wells were incubated at 371C for 2.5 h, and cells were washed twice with DMEM containing 10% FBS. Then, cells were cultured with fresh medium at 371C for 48 h, followed by the analysis of lacZ expression by the method described above. Free, unmodified Ad5.CMV-LacZ was also analyzed as a control in the same manner.
Infectivity analysis in the presence of monoclonal anti-integrin a V antibody
HeLa cells were seeded in wells (15.5 mm in diameter; 5 Â 10 4 cells/well) and cultured at 371C for 24 h. A monoclonal antibody against human integrin a v (clone AV1, mouse IgG 1 , hybridoma supernatant; Chemicon) (150 ml of a 1/2 dilution per well) was added to wells (volume of culture medium, 1.0 ml/well) and incubated at 41C for 1 h. The same volume of PBS was added to control wells and incubated in the same manner. Adenovirus-microbead conjugates were prepared by using overbiotinylated Ad5.CMV-LacZ and avidincoated silica microbeads (3.18 viral particles per microbead). These adenovirus-microbead conjugates were fully dispersed and added to wells containing HeLa cells that had been incubated with anti-integrin a v antibodies (3.75 Â 10 7 viral particles/1.18 Â 10 7 microbeads in 5 ml PBS/well). The same amount of the adenovirus-microbead conjugates was also applied to each control well, to which no anti-integrin a v antibodies had been added. These wells were incubated at 371C for 48 h, followed by the analysis of lacZ expression by the method described above. Free, unmodified Ad5.CMV-LacZ was also analyzed as a control in the same manner.
Preparation and infectivity analysis of adenovirusmicrobead conjugates with streptavidin-coated polystyrene microbeads Overbiotinylated Ad5.CMV-LacZ (6 Â 10 8 viral particles in 50 ml) was mixed with 2.4 Â 10 8 streptavidin-coated polystyrene microbeads (diameter, 0.53 mm; specific gravity, 1.06 g/cm 3 ; Bangs Laboratories, Fishers, IN, USA) at 2.5 viral particles per microbead. The mixtures were placed on ice for 30 min with occasional mixing by gentle pipetting. The resulting adenovirus-microbead conjugates were washed with PBST by three rounds of Adenoviral vectors with conditional infectivity MW Pandori and T Sano centrifugation at 16 000 g for 10 min at 41C, with each spin followed by resuspension of the conjugates in 1 ml of fresh PBST. Finally, adenovirus-microbead conjugates were resuspended in PBS without Tween 20 at a final concentration of 4.8 Â 10 9 microbeads/ml. During these manipulations, no apparent loss of microbeads was seen by visual inspection. The infectivity of the resulting adenovirus-microbead conjugates was analyzed by the method described above for overbiotinylated Ad5.CMVLacZ and its conjugates with avidin-coated silica microbeads. Free, unmodified Ad5.CMV-LacZ and free, overbiotinylated Ad5.CMV-LacZ were also analyzed as controls in the same manner.
Preparation and infectivity analysis of adenovirusmicrobead conjugates with the coattachment of Con A or alkaline phosphatase Overbiotinylated Ad5.CMV-LacZ was attached to streptavidin-coated polystyrene microbeads at 2.5 viral particles per microbead, as described above. The resulting adenovirus-microbead conjugates (in 10 ml PBS containing 4.6 Â 10 7 viral particles/1.84 Â 10 7 microbeads) were mixed with 1 ml PBS containing 2 mg biotinylated Con A (Vector Laboratories, Burlingame, CA, USA). Mixtures were placed on ice for 30 min with occasional mixing by gentle pipetting. To remove unbound biotinylated Con A, the resulting conjugates were added 1 ml of PBST and centrifuged at 41C for 10 min at 16 000 g, followed by the removal of the supernatant that contained unbound biotinylated Con A. This process was repeated, followed by the final suspension of the conjugates in PBS at a concentration of 9.2 Â 10 8 microbeads/ml. Similar conjugates were also prepared by the same method but using biotinylated alkaline phosphatase (Pierce Chemical) (2 mg/4.6 Â 10 7 microbeads), in place of biotinylated Con A, and used as controls. The infectivity of these conjugates with the coattachment of biotinylated Con A or alkaline phosphatase was analyzed by the method described above for their parental conjugates without the coattachment of biotinylated Con A or alkaline phosphatase.
Microscopic analysis of the cell association of adenovirus-microbead conjugates
The ability of adenovirus-microbead conjugates, prepared by using overbiotinylated Ad5.CMV-LacZ and streptavidin-coated polystyrene microbeads, to associate with target cells was analyzed with and without the coattachment of biotinylated Con A. Neuro-2a cells were placed in 35-mm culture wells (2 Â 10 5 cells/well) and incubated at 371C for 24 h. Adenovirus-microbead conjugates with the coattachment of biotinylated Con A were added to wells containing Neuro-2a cells (4.5 Â 10 7 viral particles/1.8 Â 10 7 microbeads in 20 ml PBS/well). Wells were incubated at room temperature for 30 min with gentle shaking, followed by the culture of cells at 371C for 24 h. Cells were washed three times with PBS and fixed with 2% paraformaldehyde. Fixed cells were washed with PBS and visualized under a light/fluorescence microscope (Axioscop 2; Carl Zeiss). For cellassociated fluorescence analysis, a set of excitation and emission filters for fluorescein (Carl Zeiss) was used to visualize fluorescence derived from streptavidin-coated polystyrene microbeads. Adenovirus-microbead conjugates without the coattachment of biotinylated Con A were analyzed as controls in the same manner.
Quantitative PCR analysis of the cell association of adenovirus-microbead conjugates Adenovirus-microbead conjugates with or without the coattachment of biotinylated Con A were prepared as described above by using overbiotinylated Ad5.CMVLacZ and streptavidin-coated polystyrene microbeads (three viral particles per microbead). HeLa cells, grown at 371C, were detached from culture plates by treatment with 5 mM EDTA. The resulting cell suspension (7.5 Â 10 5 cells in 5 ml DMEM containing 10% FBS) was mixed with adenovirus-microbead conjugates (in 15 ml PBS containing 7.2 Â 10 7 viral particles/2.4 Â 10 7 microbeads) in the absence or the presence of 200 mM methyl-a-D-glucopyranoside (Sigma) and 200 mM methyl-a-D-mannopyranoside (Sigma). The mixtures were incubated at 41C for 4 h with gentle rocking, followed by the washing of cells with PBS to remove unbound conjugates. The resulting cell samples were stored frozen overnight at À201C.
Each frozen cell sample was thawed and then analyzed in duplicate for the amount of cell-associated Ad5.CMV-LacZ by quantitative PCR using a Prism 7700 Sequence Detection System (Applied Biosystems) with a pair of primers and a probe that are specific to a segment of the genome of Ad5.CMV-LacZ. The sequences of the primers used are: 5 0 -CGACGGATGTGGCAAAAGT-3 0 and 5 0 -CCTAAAACCGCGCGAAAA-3 0 . The probe used has a sequence of 5 0 -CACCGGCGCACACCAAAAACG-3 0 , labeled with 6-FAM (6-carboxyfluorescein) and TAMRA (carboxymethylrhodamine) at the 5 0 -and 3 0 -termini, respectively. As a control, adenovirus-microbead conjugates without the coattachment of biotinylated Con A were analyzed in the same manner. Known amounts of free, unmodified Ad5.CMV-LacZ were used as standards for quantitation. All quantitative PCR analysis was performed at the TaqMan Real-time PCR Core of the Beth Israel Deaconess Medical Center.
